報價延遲最少15分鐘:2025/07/17 16:43 EDT
盤後時段
|
||||
|
6.47 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
6.38
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.58/-4.76
|
|
企業價值
293.79M
|
| 資產負債 |
|
每股賬面淨值
10.99
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
210.78M
|
|
每股收益
2.30
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/07/17 16:43 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion. |
